中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(12): 2761-2764

Value of body fat parameters in predicting the severity of acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2020.12.024

  • Department of Gastroenterology,The Affiliated Hospital of Southwest Medical University

  • Received Date: 2020-05-07
  • Published Date: 2020-12-20
    Abstract

  • Objective To investigate the correlation between body fat parameters and the severity of acute pancreatitis( AP) and the value of body fat parameters in predicting the severity of AP. Methods A retrospective analysis was performed for the clinical data of 229 patients with AP who were treated in Department of Gastroenterology in The Affiliated Hospital of Southwest Medical University from June 2016 to June 2019. According to the diagnostic criteria for AP,the patients were divided into mild acute pancreatitis( MAP) group,moderate-severe acute pancreatitis( MSAP) group( all P < 0. 05),and severe acute pancreatitis( SAP) group,and CT images were used to calculate related body fat parameters [visceral adipose tissue( VAT),subcutaneous adipose tissue( SAT),total adipose tissue( TAT),abdominal muscle area( AMA),VAT/TAT ratio( VTR),and visceral fat-to-muscle ratio( VMR) ]. A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. A logistic regression analysis was used to investigate the correlation of the body fat parameters with AP severity. The receiver operating characteristic( ROC) curve was established for each body fat parameter and the area under the ROC curve( AUC) was calculated,and then the Youden index was calculated to determine the optimal cut-off value. Results There were significant differences in age,VAT,TAT,AMA,VTR,and VMR between the three groups( F = 4. 15,35. 25,73. 02,7. 09,462. 30,and 139. 4,all P < 0. 05),and further comparison showed that compared with the MAP group,the MSAP group and the SAP group had significant increases in VAT,TAT,VTR,and VMR( all P<0. 05) and a significant reduction in AMA( all P < 0. 05). The SAP group had significantly higher VAT,VTR,and VMR than the MSAP group( all P < 0. 05). VMR had the largest AUC of 0. 84( 95% confidence interval: 0. 76-0. 92) in predicting MSAP and SAP,and had the cut-off value of 1. 38 in predicting the severity of AP,with a sensitivity of 67. 5% and a specificity of 90. 6%. Conclusion Body fat parameters are correlated the severity of AP. VMR has a unique value in predicting the severity of AP and can be included in the future scoring models for predicting AP severity.

     

    • FullText(HTML)
    • References(21)
  • [1] LIN XH,LI YY. Progress of mechanism and related treatment of acute pancreatitis[J]. Chin J Pathophysiol,2010,26(5):1029-1032,1040.(in Chinese)林旭红，李永渝．急性胰腺炎发病机制及相关治疗的研究进展[J]．中国病理生理杂志，2010,26(5):1029-1032,1040.
    [2] BANKS PA,BOLLEN TL,DERVENIS C,et al. Classification of acute pancreatitis—2012:Revision of the Atlanta classification and definitions by international consensus[J]. Gut,2013,62(1):102-111.
    [3] IGNATAVICIUS P,GULLA A,CERNAUSKIS K,et al. How severe is moderately severe acute pancreatitis? Clinical validation of revised 2012 Atlanta Classification[J]. World J Gastroenterol,2017,23(43):7785-7790.
    [4] WANG Y,RAO YY,GUO J,et al. Evaluation and analysis of the current guidelines for acute pancreatitis using Appraisal of Guidelines for Research and Evaluation II[J]. J Clin Hepatol,2018,34(6):1225-1230.(in Chinese)王宇，饶友义，郭军，等．AGREEⅡ系统对现行国内外急性胰腺炎指南的评价分析[J]．临床肝胆病杂志，2018,34(6):1225-1230.
    [5] XIAN LN,YANG YZ,CHEN W,et al. The application value of chemokine MIP-1α，MIP-1βand APACHEⅡscore in the severity and prognosis of acute pancreatitis[J]. Traum Crit Med,2018,6(1):14-17.(in Chinese)冼丽娜，杨远征，陈伟，等．巨噬细胞炎性蛋白-1α、巨噬细胞炎性蛋白-1β与急性生理和慢性健康状况评分在急性胰腺炎严重程度及预后中应用价值[J]．创伤与急危重病医学，2018,6(1):14-17.
    [6] NATU A,STEVENS T,KANG L,et al. Visceral adiposity predicts severity of acute pancreatitis[J]. Pancreas,2017,46(6):776-781.
    [7] NOEL P,PATEL K,DURGAMPUDI C,et al. Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections[J]. Gut,2016,65(1):100-111.
    [8] Pancreas Study Group,Chinese Society of Gastroenterology,Chinese Medical Association,Editorial Board of Chinese Journal of Pancreatology,Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis(Shanghai,2013)[J]. J Clin Hepatol,2013,29(9):656-660.(in Chinese)中华医学会消化病学分会胰腺疾病学组，《中华胰腺病杂志》编辑委员会，《中华消化杂志》编辑委员会．中国急性胰腺炎诊治指南(2013年，上海)[J]．临床肝胆病杂志，2013,29(9):656-660.
    [9] MARTNEZ J,SNCHEZ-PAYJ,PALAZN JM,et al. Is obesity a risk factor in acute pancreatitis? A meta-analysis[J]. Pancreatology,2004,4(1):42-48.
    [10] YOON SB,CHOI MH,LEE IS,et al. Impact of body fat and muscle distribution on severity of acute pancreatitis[J]. Pancreatology,2017,17(2):188-193.
    [11] MA ZJ,MOU CP. The role of adiponectin in the inflammatory reaction of cardiac syndrome X[J]. Heilongjiang Med Pharm,2008,31(5):42-43.(in Chinese)马振晶，牟春平．脂联素在心脏X综合征炎性反应中的作用[J]．黑龙江医药科学，2008,31(5):42-43.
    [12] HAN LF,BIAN XJ,GUO YX,et al. Correlation between visceral adipose tissue and severity of acute pancreatitis[J].Chin J Crit Care Med,2015,35(7):593-597.(in Chinese)韩良富，卞晓洁，郭艳霞，等．内脏脂肪组织与急性胰腺炎严重程度的相关性分析[J]．中国急救医学，2015,35(7):593-597.
    [13] KARPAVICIUS A,DAMBRAUSKAS Z,SILEIKIS A,et al. Value of adipokines in predicting the severity of acute pancreatitis:Comprehensive review[J]. World J Gastroenterol,2012,18(45):6620-6627.
    [14] NOEL P,PATEL K,DURGAMPUDI C,et al. Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections[J]. Gut,2016,65(1):100-111.
    [15] KE L,NI HB,SUN JK,et al. Risk factors and outcome of intraabdominal hypertension in patients with severe acute pancreatitis[J]. World J Surg,2012,36(1):171-178.
    [16] LU B,QIAN JM. Research progress of severe acute pancreatitis etiology and pathogenesis[J]. Chin J Pract Surg,2012,32(7):590-592.(in Chinese)芦波，钱家鸣．重症急性胰腺炎病因及发病机制研究进展[J]．中国实用外科杂志，2012,32(7):590-592.
    [17] KIM JA,ROH E,HONG SH,et al. Association of serum sclerostin levels with low skeletal muscle mass:The Korean Sarcopenic Obesity Study(KSOS)[J]. Bone,2019,128:115053.
    [18] WANNAMETHEE SG,ATKINS JL. Muscle loss and obesity:The health implications of sarcopenia and sarcopenic obesity[J]. Proc Nutr Soc,2015,74(4):405-412.
    [19] ABETE I,KONIECZNA J,ZULET MA,et al. Association of lifestyle factors and inflammation with sarcopenic obesity:Data from the PREDIMED-Plus trial[J]. J Cachexia Sarcopenia Muscle,2019,10(5):974-984.
    [20] CHENG TJ,HAN XQ,SONG ZC,et al. Clinical value of tissue harmonic imaging and CT scanning in ultrasonographic diagnosis of acute pancreatitis[J]. Chin J Ultrasound Med,2004,20(7):521-523.(in Chinese)程天江，韩兴权，宋振才，等．组织谐波成像与CT扫描在急性胰腺炎诊断中的应用价值[J]．中国超声医学杂志，2004,20(7):521-523.
    [21] YIP C,DINKEL C,MAHAJAN A,et al. Imaging body composition in cancer patients:Visceral obesity,sarcopenia and sarcopenic obesity may impact on clinical outcome[J]. Insights Imaging,2015,6(4):489-497.
    • Relative Articles

  • Relative Articles

    [1]Xiaoxuan XIE, Lina DU, Ziyun GUO, Yan YANG. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2024, 40(1): 199-203. doi: 10.12449/JCH240133
    [2]Long HUANG, Yu CHEN, Qiao WU, Zhongping DUAN. Effect of Shuganning injection on the model of cholestasis - type chlorpromazine - induced liver injury constructed by a new tissue - engineered liver[J]. Journal of Clinical Hepatology, 2022, 38(3): 587-593. doi: 10.3969/j.issn.1001-5256.2022.03.018
    [3]Huaqian XU, Meng WEI, Xue ZHANG, Hai YI, Fangyi FAN, Aiping HUANG, Shanhong TANG. Diffuse large B-cell lymphoma with severe cholestasis as the main manifestation: A case report[J]. Journal of Clinical Hepatology, 2022, 38(12): 2821-2823. doi: 10.3969/j.issn.1001-5256.2022.12.025
    [4]Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
    [5]Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1179-1182. doi: 10.3969/j.issn.1001-5256.2022.05.043
    [6]Jing LI, Kuiyang ZHENG, Beibei ZHANG. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. Journal of Clinical Hepatology, 2021, 37(10): 2482-2487. doi: 10.3969/j.issn.1001-5256.2021.10.048
    [7]WU Rong, LING AiMin. Primary biliary cirrhosis with autoimmune hemolytic anemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(12): 2795-2797. doi: 10.3969/j.issn.1001-5256.2020.12.030
    [8]Hua HaiYang, Li JianHui, Su Bin, Xuan XiaoYu. Liver subcapsular biliary cyst successfully treated by endoscopic retrograde cholangiopancreatography: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1354-1355. doi: 10.3969/j.issn.1001-5256.2020.06.034
    [9]Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
    [10]Zhou Fang, Li XiaoQin, Wang RuiFeng, Sun Bo. X-linked lymphoproliferative disease type 2 with cholestatic liver disease as initial manifestation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1811-1814. doi: 10.3969/j.issn.1001-5256.2019.08.034
    [11]Kan YanTing, Yang YongFeng. Role of cholestatic liver disease-related genes in intrahepatic cholestasis of pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1439-1443. doi: 10.3969/j.issn.1001-5256.2019.07.006
    [12]Song YuanZong. Research advances in the pathogenesis, clinical manifestations, and diagnosis/treatment of sodium-taurocholate cotransporting polypeptide deficiency[J]. Journal of Clinical Hepatology, 2019, 35(8): 1690-1692. doi: 10.3969/j.issn.1001-5256.2019.08.007
    [13]Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
    [14]Zhang XuQian, Zhao ChunShan, Liu WenTian, Wang BangMao, Zhou Lu. Elevated serum GGT level in recovery phase of cholestatic liver disease reveals good prognosis: a case report [J]. Journal of Clinical Hepatology, 2016, 32(4): 774-775. doi: 10.3969/j.issn.1001-5256.2016.04.037
    [15]Shen FeiFei, Lu LunGen. Liver alkaline phosphatase: a marker of cholestasis and bile duct injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 1026-1030. doi: 10.3969/j.issn.1001-5256.2016.05.052
    [16]Li Hua, Li YiMing, Lu Le. Mechanism of α-naphthyl isothiocyanate inducing cholestatic hepatitis: a preliminary study[J]. Journal of Clinical Hepatology, 2016, 32(5): 933-937. doi: 10.3969/j.issn.1001-5256.2016.05.026
    [17]Li Lei, Li Bing, Ding HuiGuo. Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes[J]. Journal of Clinical Hepatology, 2016, 32(3): 522-525. doi: 10.3969/j.issn.1001-5256.2016.03.026
    [18]Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
    [19]Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
    [20]Qu Ying, Xu MingYi, Lu LunGen. Current progress in understanding of cholestasis and autoimmune liver diseases——Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(2): 222-225.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(8)

    1. 张连峰，杨丽敏. 胸腺肽肠溶片联合聚乙二醇干扰素对慢性肝炎患者的治疗效果及其相关指标的影响. 中国当代医药. 2020(04): 50-52 .
    2. 王雪云，孙敏，赵巧云，李红军，王先芝，郑玉山，边城. 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察. 医学信息. 2020(04): 144-146 .
    3. 刘征. 恩替卡韦联合α-干扰素对慢性乙型肝炎患者血清ALT复常率的影响. 淮海医药. 2020(02): 181-183 .
    4. 李淑，彭雁忠，胡国信，齐明华，武敬. 聚乙二醇干扰素治疗低水平HBsAg慢性乙肝患者疗效. 中国热带医学. 2020(07): 676-681 .
    5. 嵇玮嘉，颜学兵. 聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较. 临床肝胆病杂志. 2019(02): 309-314 . 本站查看
    6. 吴明杰. 聚乙二醇干扰素α-2b对慢性乙型肝炎的作用分析. 中国继续医学教育. 2019(12): 142-144 .
    7. 张珊，王艺璇，孙静，朱琳，王凤水，邢卉春. 干扰素联合抗病毒治疗对提高核苷（酸）类药物经治慢性乙型肝炎患者表面抗原阴转率的影响. 中华实验和临床感染病杂志(电子版). 2019(04): 273-280 .
    8. 郭志勇，贺文娟，裴军芳. 聚乙二醇干扰素α-2a注射液联合替诺福韦酯治疗e抗原阳性慢性乙型肝炎疗效分析. 中国药物与临床. 2019(22): 3944-3946 .

    Other cited types(4)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 9.0 %FULLTEXT: 9.0 %META: 85.7 %META: 85.7 %PDF: 5.3 %PDF: 5.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.3 %其他: 4.3 %其他: 1.0 %其他: 1.0 %China: 0.3 %China: 0.3 %India: 0.1 %India: 0.1 %Rijeka: 0.2 %Rijeka: 0.2 %Tiruchi: 0.1 %Tiruchi: 0.1 %United Kingdom: 0.3 %United Kingdom: 0.3 %[]: 0.1 %[]: 0.1 %上海: 4.0 %上海: 4.0 %东莞: 0.1 %东莞: 0.1 %乌鲁木齐: 0.5 %乌鲁木齐: 0.5 %兰州: 0.1 %兰州: 0.1 %北京: 10.0 %北京: 10.0 %南京: 0.1 %南京: 0.1 %南充: 0.1 %南充: 0.1 %南宁: 0.1 %南宁: 0.1 %吉林: 0.5 %吉林: 0.5 %哈尔滨: 0.1 %哈尔滨: 0.1 %塔斯马尼亚: 1.3 %塔斯马尼亚: 1.3 %天津: 0.3 %天津: 0.3 %娄底: 0.1 %娄底: 0.1 %宁波: 0.1 %宁波: 0.1 %密蘇里城: 0.5 %密蘇里城: 0.5 %广元: 0.3 %广元: 0.3 %广州: 0.3 %广州: 0.3 %张家口: 2.8 %张家口: 2.8 %成都: 0.3 %成都: 0.3 %成都市简阳: 0.1 %成都市简阳: 0.1 %新德里: 0.2 %新德里: 0.2 %无锡: 0.6 %无锡: 0.6 %昆明: 0.1 %昆明: 0.1 %晋城: 0.1 %晋城: 0.1 %杭州: 0.3 %杭州: 0.3 %武汉: 0.5 %武汉: 0.5 %沈阳: 0.2 %沈阳: 0.2 %泸州: 0.2 %泸州: 0.2 %济南: 0.1 %济南: 0.1 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.1 %深圳: 0.1 %漯河: 0.1 %漯河: 0.1 %眉山: 0.2 %眉山: 0.2 %石家庄: 0.2 %石家庄: 0.2 %秦皇岛: 0.1 %秦皇岛: 0.1 %罗奥尔凯埃: 0.2 %罗奥尔凯埃: 0.2 %芒廷维尤: 37.6 %芒廷维尤: 37.6 %莫斯科: 1.1 %莫斯科: 1.1 %衢州: 0.1 %衢州: 0.1 %西宁: 24.3 %西宁: 24.3 %西安: 0.1 %西安: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %运城: 1.1 %运城: 1.1 %通化: 0.3 %通化: 0.3 %长春: 2.8 %长春: 2.8 %长治: 0.2 %长治: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他ChinaIndiaRijekaTiruchiUnited Kingdom[]上海东莞乌鲁木齐兰州北京南京南充南宁吉林哈尔滨塔斯马尼亚天津娄底宁波密蘇里城广元广州张家口成都成都市简阳新德里无锡昆明晋城杭州武汉沈阳泸州济南海得拉巴深圳漯河眉山石家庄秦皇岛罗奥尔凯埃芒廷维尤莫斯科衢州西宁西安诺沃克运城通化长春长治驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (4554) PDF downloads(81) Cited by(12)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[83]TodayPV[140]Online[28]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return